O
SIOX

OppenheimerFunds’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

OppenheimerFunds’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-36,837
Closed -$3.66M – 1900
2016
Q4 		$3.66M Buy
36,837
+1,538
+4% +$162K ﹤0.01% 860
2016
Q3 		$3.95M Buy
35,299
+1,078
+3% +$129K 0.01% 839
2016
Q2 		$3.52M Buy
34,221
+4,189
+14% +$419K ﹤0.01% 827
2016
Q1 		$2.76M Buy
30,032
+1,279
+4% +$136K ﹤0.01% 863
2015
Q4 		$4.15M Buy
28,753
+769
+3% +$100K 0.01% 843
2015
Q3 		$2.89M Buy
27,984
+1,159
+4% +$136K ﹤0.01% 837
2015
Q2 		$4.37M Buy
+26,825
New +$4.55M 0.01% 841

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return

OppenheimerFunds's SIOX Position: Q1 2017 in Review

OppenheimerFunds sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2017, closing a stake of 36,837 shares — an estimated $3.66M sold.

OppenheimerFunds first reported a position in SIOX in Q2 2015 and held it in 7 quarters. The position peaked at $4.37M in Q2 2015. 97 funds tracked by Wall St. Rank hold SIOX as of Q1 2017.

  • OppenheimerFunds reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • OppenheimerFunds sold 36,837 Sio Gene Therapies Inc. Common Stock shares in Q1 2017, an estimated $3.66M.
  • OppenheimerFunds first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 7 quarters.
  • OppenheimerFunds's Sio Gene Therapies Inc. Common Stock position peaked at $4.37M in Q2 2015.
  • 97 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2017.

Based on OppenheimerFunds's 13F filing for Q1 2017, filed 11 May 2017.